Washington: A combination of symptom and viral rebound after untreated COVID-19 infection is rare, occurring in only three per cent of study participants, an analysis of a COVID-19 trial has found.
Widespread use of nirmatrelvir -- a recommended treatment for outpatients with mild
to moderate COVID-19 -- has been accompanied by reports of worsening symptoms and virologic rebound after treatment completion, the researchers said.
Virologic rebound has also been reported in persons who did not receive nirmatrelvir therapy, they said.